Personal tools
You are here: Home Video report & Promotions
Document Actions

Video report & Promotions

Up one level

Video report of the BioBusiness Event 2008 and video promotions of biotech companies in the Amsterdam Metroplitan Area.

BioBusiness Event 2008
The Amsterdam BioMed Cluster gave Cluster partners the opportunity to present themselves and “do business” during the BioBusiness Event 2008 held May 21 in the RAI, Amsterdam. Cluster partners “on display” were research institutes AMC, Sanquin, VU/VUmc, NKI-AvL and UvA and university spin offs A-Skin, Arthrogen and DCPrime.
Amsterdam BioMed CLuster
The Amsterdam BioMed Cluster has the ambition to turn the larger Amsterdam area into an internationally attractive and innovative bioregion.
Agendia
Gene expression analysis-based cancer diagnostics.
Avantium
Product development, Services and Equipment in Energy, Chemical and Pharma sectors aimed at catalysis and crystallization research using high-throughput technology.
Bmeye B.V.
BMEYE is dedicated to improving patient care and safety by designing, manufacturing and marketing continuous, non-invasive hemodynamics monitoring systems. The real time monitoring of vital signs such as blood pressure and cardiac output allows early recognition and treatment of rapid changes in critical care settings and improves diagnosis and management of cardiovascular conditions in non-critical circumstances. BMEYE provides safe, precise and easy to use solutions to bring affordable, reliable hemodynamic monitoring and diagnostics into daily patient care.
City of Amsterdam
Ask the managers of foreign companies in Amsterdam what sets this region apart from the other interesting places for doing business in Europe, and you’ll get any number of different answers. One will stress the fact that nearly all the European multinationals are represented, if not actually based; here, another will comment on the international mindset of Amsterdammers, and the multicultural strengths of the city. Meanwhile, someone else will praise the excellent physical and digital networks, or the inspiring energy of this centuries-old trading city with its rich cultural heritage. But they will all agree on one important thing: Amsterdam is the director of Europe.
DEAM Corporation
Development and fabrication of instruments for minimally invasive therapies.
Escobar advertising
 
Genzyme
Genzyme’s products and services are focused on rare inherited disorders, kidney disease, orthopaedics, transplant, cancer, and diagnostic testing. Genzyme’s commitment to innovation continues today with a substantial research and development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
KSYOS TeleMedical Centre
 
O2view
 
Pepscan
Developing Immunotherapeutics in Oncology.
Personal Space Technologies
Solutions for the intuitive rapid analysis of complex 3D and 4D medical images.
Science Park Amsterdam
The variety of research initiatives and service offerings creates an environment in which knowledge valorisation is clearly visible in new initiatives and start-up businesses: the Science Park Amsterdam houses over 80 (starting) companies.
Syntens
Syntens focuses on helping medium and small sized enterprises to innovate quicker, better and sooner, by being a full partner to the management and R&D directors in health-related companies.
TIPb
Improving large-scale biochemical processes using readily available process data.
Winclove
Development and production of general purpose probiotic food supplements as well as tailor made designed probiotic food supplements for specific purposes.
clmn_image

It’s business stupid

What is it with the Dutch that they have such difficulty grabbing business opportunities in a changing world? We have the brains, we have the money and the opportunities are plenty. Still, during the last 40 years hardly any company of substantial size has emerged next to the old industry in the AEX.  Oil, food, materials and financial services dominate the landscape.

We have left the environmental challenges to environmentalists, rather then building innovative businesses in solar or wind energy to help face them. We have exported our knowledge on agriculture around the world, and now that we can more intelligently engineer crops we let the opportunity pass due to invalid arguments around GMOs. Now that  “kweekersrecht” is being substituted by patent law we complain instead of adapt.

Continue

 

Powered by Plone CMS, the Open Source Content Management System

This site conforms to the following standards: